GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wuhan Hiteck Biological Pharma Co Ltd (SZSE:300683) » Definitions » EV-to-Revenue

Wuhan Hiteck Biological Pharma Co (SZSE:300683) EV-to-Revenue : 3.08 (As of Sep. 24, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Wuhan Hiteck Biological Pharma Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Wuhan Hiteck Biological Pharma Co's enterprise value is ¥1,847.4 Mil. Wuhan Hiteck Biological Pharma Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was ¥600.5 Mil. Therefore, Wuhan Hiteck Biological Pharma Co's EV-to-Revenue for today is 3.08.

The historical rank and industry rank for Wuhan Hiteck Biological Pharma Co's EV-to-Revenue or its related term are showing as below:

SZSE:300683' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.19   Med: 5.77   Max: 12.1
Current: 3.08

During the past 11 years, the highest EV-to-Revenue of Wuhan Hiteck Biological Pharma Co was 12.10. The lowest was 2.19. And the median was 5.77.

SZSE:300683's EV-to-Revenue is ranked worse than
60.6% of 1005 companies
in the Drug Manufacturers industry
Industry Median: 2.27 vs SZSE:300683: 3.08

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-09-24), Wuhan Hiteck Biological Pharma Co's stock price is ¥20.92. Wuhan Hiteck Biological Pharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was ¥4.44. Therefore, Wuhan Hiteck Biological Pharma Co's PS Ratio for today is 4.71.


Wuhan Hiteck Biological Pharma Co EV-to-Revenue Historical Data

The historical data trend for Wuhan Hiteck Biological Pharma Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Hiteck Biological Pharma Co EV-to-Revenue Chart

Wuhan Hiteck Biological Pharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.13 6.76 10.91 5.17 6.18

Wuhan Hiteck Biological Pharma Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.65 6.81 6.18 4.05 3.26

Competitive Comparison of Wuhan Hiteck Biological Pharma Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Wuhan Hiteck Biological Pharma Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Hiteck Biological Pharma Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wuhan Hiteck Biological Pharma Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Wuhan Hiteck Biological Pharma Co's EV-to-Revenue falls into.



Wuhan Hiteck Biological Pharma Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Wuhan Hiteck Biological Pharma Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1847.395/600.459
=3.08

Wuhan Hiteck Biological Pharma Co's current Enterprise Value is ¥1,847.4 Mil.
Wuhan Hiteck Biological Pharma Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥600.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuhan Hiteck Biological Pharma Co  (SZSE:300683) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Wuhan Hiteck Biological Pharma Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=20.92/4.442
=4.71

Wuhan Hiteck Biological Pharma Co's share price for today is ¥20.92.
Wuhan Hiteck Biological Pharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4.44.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuhan Hiteck Biological Pharma Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Wuhan Hiteck Biological Pharma Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan Hiteck Biological Pharma Co Business Description

Traded in Other Exchanges
N/A
Address
Hite Science and Technology Park, Wuhan Economic and Technological Development Zone, Hubei Province, Wuhan, CHN, 430056
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.
Executives
Yan Jie Director
Li Sheng Qiang Executives

Wuhan Hiteck Biological Pharma Co Headlines

No Headlines